What is the saturation theory regarding testosterone and prostate receptors?

The saturation theory suggests that androgen receptors in the prostate become saturated at relatively low testosterone levels (around 200-250 ng/dL). Beyond this point, additional testosterone may offer limited further benefits to the prostate.

Can low testosterone levels be linked to more aggressive prostate cancer?

Some research suggests that lower testosterone might be associated with higher-grade prostate cancer. Tumors that are less reliant on androgens might be more aggressive and harder to treat.

How is the Androgen Receptor Activity (AR Score) used in prostate cancer treatment?

The AR score helps assess tumor aggressiveness. For localized, higher-grade prostate cancers (e.g., Gleason 3+4), a low AR score might suggest a less androgen-dependent tumor, potentially influencing treatment choices like preferring surgery over ADT.

Is it okay to continue TRT if diagnosed with low-grade prostate cancer?

Yes, if you have low-grade prostate cancer and are on TRT, continuing it is generally considered acceptable. The evidence does not show that exogenous testosterone accelerates or propagates existing prostate cancer.

Why is surgery often preferred over radiation and ADT for localized prostate cancer?

Surgery allows for the continuation of TRT, avoiding the significant side effects of Androgen Deprivation Therapy (ADT). ADT is often required with radiation, which can induce hypogonadism and symptoms, impacting quality of life.

Why don't men with prostate cancer routinely receive adjuvant androgen deprivation therapy like women with breast cancer receive anti-estrogen therapy?

Prostate cancer has a highly sensitive biomarker, PSA, which allows for precise monitoring for recurrence. This enables a 'sniper' approach with early salvage therapies, unlike breast cancer which lacks such a sensitive biomarker and uses a more proactive 'bazooka' approach with adjuvant therapy.

310 - The relationship between testosterone and prostate cancer, TRT, and more

Peter Attia MD

Science & Technology4 min read49 min video

Jul 22, 2024|50,611 views|849|73

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

TL;DR

Testosterone doesn't cause prostate cancer; low T may link to aggressive forms. TRT is generally safe.

Key Insights

The Traverse trial found no increased risk of prostate cancer diagnosis or cardiovascular events with exogenous testosterone therapy.

Low testosterone levels may be associated with more aggressive forms of prostate cancer, not caused by testosterone supplementation.

The 'saturation theory' suggests prostate tissue reaches androgen receptor saturation at relatively low testosterone levels, limiting further growth impact.

Testosterone replacement therapy (TRT) is generally safe for men with low-grade prostate cancer, and continuing TRT may be advisable.

Advanced prostate cancer research is exploring molecular signatures, like AR activity, to guide treatment decisions and personalize therapy.

High-grade prostate cancers may rely less on traditional androgen receptor signaling, suggesting alternative growth pathways.

THE TRAVERSE TRIAL AND PROSTATE CANCER RISK

The recent Traverse trial investigated whether exogenous testosterone increases the risk of cardiovascular events (ASCVD) and prostate cancer. While the primary outcome showed no increased ASCVD risk, a secondary analysis focused on prostate cancer. The study enrolled hypogonadal men with symptoms, aiming to restore testosterone to eugonadal levels. Even with a small increase in testosterone levels and a significant dropout rate, the trial found no statistically significant increase in prostate cancer diagnoses. The low number of prostate cancers detected overall (23 out of over 5300 men) suggests reassurance, particularly for men with low baseline PSAs.

UNDERSTANDING PSA AND PROSTATE CANCER DETECTION

The Traverse trial data indicated that men diagnosed with prostate cancer had higher average PSA levels and greater PSA increases during the study compared to those without cancer. This reinforces the utility of PSA as a screening tool, even in men undergoing testosterone replacement therapy (TRT). Most men in the trial experienced minimal PSA changes. These findings suggest that monitoring PSA and its changes remains a reliable method for detecting potential prostate cancer in men on TRT, offering a low-risk profile for the therapy itself in this context.

THE SATURATION THEORY AND ANDROGEN RECEPTOR ACTIVITY

A key concept discussed is the 'saturation theory,' which posits that prostate tissue reaches a saturation point for androgen receptors at relatively low serum testosterone levels, around 200-250 ng/dL. Beyond this point, additional testosterone may not significantly impact prostate growth or cancer progression. This theory helps explain why testosterone supplementation doesn't necessarily fuel prostate cancer, as the receptors are already largely saturated. Benign prostate cells, with higher densities of androgen receptors, may be more sensitive to testosterone than cancerous cells, contributing to BPH symptoms rather than cancer growth.

MOLECULAR SUBTYPES AND PROSTATE CANCER AGGRESSIVENESS

Research is increasingly focusing on the molecular characteristics of prostate tumors. A significant finding is the correlation between lower testosterone levels and higher-grade prostate cancer, suggesting that more aggressive cancers might develop in or adapt to a low-androgen environment. These aggressive tumors may rely less on traditional Androgen Receptor (AR) signaling and more on alternative growth pathways. This understanding is crucial for personalized treatment, as tumors with low AR activity might behave differently and have different vulnerabilities than those with high AR activity.

THE ROLE OF AR SIGNATURES IN TREATMENT DECISIONS

Advanced assays, like the Decipher GRID signature, analyze gene expression in prostate cancer tissue to assess AR activity. This molecular profiling, available through CLIA-certified labs, can help stratify risk, especially in intermediate-grade cancers (e.g., Gleason 3+4). For localized prostate cancer, a low AR signature in a higher-grade tumor might support surgical intervention over radiation combined with Androgen Deprivation Therapy (ADT), potentially avoiding the significant morbidity associated with ADT. Conversely, high AR activity may indicate greater sensitivity to ADT.

TRT CONSIDERATIONS IN HYPOGONADAL MEN WITH PROSTATE CANCER

For symptomatic hypogonadal men without cancer, TRT is generally advised to maintain cardiovascular, bone, muscle, and cognitive health. The approach changes for men with prostate cancer. For low-grade cancers under surveillance, continuing TRT is often recommended, as there's no evidence that exogenous testosterone accelerates cancer progression. The rationale is that a eugonadal state supports overall health, and biologically, testosterone acts as a differentiation factor for prostate cells. For higher-grade cancers requiring treatment, particularly radiation, testosterone levels are typically suppressed, highlighting a key difference in management strategies.

SURGERY VERSUS RADIATION AND ANDROGEN DEPRIVATION

When choosing between surgery and radiation for localized prostate cancer, the role of Androgen Deprivation Therapy (ADT) is a significant factor. Surgery offers the possibility of maintaining testosterone levels, potentially allowing continued TRT, thereby avoiding the profound negative impacts of ADT. Radiation therapy, while highly effective, necessitates aggressive androgen suppression, often leading to induced hypogonadism. The decision-making process heavily weighs the potential for systemic hormonal therapy side effects against the invasiveness and potential outcomes of each primary treatment modality.

PSA AS A BIOMARKER AND ADJUVANT THERAPY DIFFERENCES

A key distinction between prostate cancer and breast cancer management lies in the utility of PSA as a highly sensitive biomarker. Unlike breast cancer, where adjuvant anti-estrogen therapy is standard even after complete resection, prostate cancer's PSA monitoring allows for a more conservative approach to adjuvant ADT. This sensitivity enables early detection of recurrence, facilitating prompt salvage therapies rather than a universal 'bazooka' approach of upfront ADT, making prostate cancer management more tailored and potentially less morbid.

Mentioned in This Episode

●Supplements

●Software & Apps

●Tools

●Companies

●Organizations

●Books

●Studies Cited

●Concepts

●People Referenced

Common Questions

The Traverse trial found no increase in prostate cancer diagnosis with TRT in men with low testosterone and low PSA. While not definitive, it's reassuring. However, changes in PSA while on TRT should still be monitored closely.

Topics

Traverse Trial Androgen Receptor PSA Levels Gleason Score AR Score Molecular Profiling Hypogonadism Androgen Deprivation Therapy (ADT)BPH Saturation Theory TRT Risks

Mentioned in this video

drugDarolutamide

A third-generation oral androgen receptor inhibitor used for prostate cancer treatment.

drugAnti-estrogen therapy

Hormonal therapy used for ER-positive breast cancer, which can have significant side effects like osteoporosis and induced menopause.

conceptCardiovascular health

One of the key health areas that maintaining eugonadal testosterone levels is believed to support.

conceptBone health

A health benefit associated with maintaining eugonadal testosterone levels.

conceptASCVD

Atherosclerotic cardiovascular disease; the Traverse trial found no increased risk associated with exogenous testosterone.

conceptBenign Prostatic Hyperplasia (BPH)

A non-cancerous enlargement of the prostate gland. Studies suggest testosterone supplementation may worsen BPH symptoms due to the sensitivity of benign cells.

conceptAndrogen Receptor Activity Signature (AR Score)

A molecular signature developed to assess Androgen Receptor activity in prostate cancer cells, correlating with aggressiveness.

conceptGRID signature

A specific AR signature assay available through physicians, providing insight into tumor AR activity.

drugEnzalutamide

A nonsteroidal antiandrogen medication used to treat prostate cancer, potentially beneficial for AR-low tumors when combined with radiation.

drugApalutamide

An androgen receptor inhibitor used in the treatment of prostate cancer, potentially beneficial in combination therapy.

conceptCognitive function

Mental capability that is discussed as being supported by adequate testosterone levels.

conceptCell-free DNA

DNA fragments found in blood that can be analyzed to detect cancer markers and monitor for recurrence, particularly relevant for liquid biopsies.

toolPSA

Prostate-Specific Antigen; a biomarker used for screening prostate cancer. Mean PSA in the Traverse trial was low (0.9).

conceptSaturation Theory

A theory proposing that androgen receptors become saturated at certain testosterone levels, leading to diminished effects with further supplementation.

conceptGleason Score

A system used to grade prostate cancer based on how abnormal the cancer cells look under a microscope. Gleason 3+3 signifies a low-grade tumor.

softwareDecipher

A company that offers a CLIA-approved assay (Decipher score) for molecular profiling of prostate cancer aggressiveness.

studyTraverse Trial

A study that investigated whether exogenous testosterone increases the risk of cardiovascular events (ASCVD) and prostate cancer in men.

organizationNRG

A clinical trials group conducting research on prostate cancer treatments, including those involving Androgen Deprivation Therapy (ADT) and genomics.

conceptER positive breast cancer

A type of breast cancer that relies on estrogen to grow, often treated with anti-estrogen therapy.

toolLiquid biopsies

Tests that can detect cancer DNA in the blood, offering a less invasive way to monitor for recurrence, potentially applicable to breast cancer like prostate cancer.

drugDihydrotestosterone (DHT)

otherAndrogen Deprivation Therapy (ADT)